Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Asset Writedowns and Impairment (2019 - 2025)

Historic Asset Writedowns and Impairment for Fortress Biotech (FBIO) over the last 8 years, with Q3 2025 value amounting to $76000.0.

  • Fortress Biotech's Asset Writedowns and Impairment changed N/A to $76000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $873000.0, marking a year-over-year decrease of 6704.42%. This contributed to the annual value of $3.7 million for FY2024, which is 1746.74% up from last year.
  • Per Fortress Biotech's latest filing, its Asset Writedowns and Impairment stood at $76000.0 for Q3 2025.
  • Fortress Biotech's 5-year Asset Writedowns and Impairment high stood at $3.1 million for Q2 2023, and its period low was -$441000.0 during Q2 2025.
  • Its 5-year average for Asset Writedowns and Impairment is $445187.5, with a median of $73000.0 in 2021.
  • As far as peak fluctuations go, Fortress Biotech's Asset Writedowns and Impairment crashed by 26710.53% in 2021, and later soared by 1003870.97% in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's Asset Writedowns and Impairment stood at $115000.0 in 2021, then skyrocketed by 138.26% to $274000.0 in 2022, then surged by 1047.08% to $3.1 million in 2023, then crashed by 66.82% to $1.0 million in 2024, then tumbled by 92.71% to $76000.0 in 2025.
  • Its Asset Writedowns and Impairment was $76000.0 in Q3 2025, compared to -$441000.0 in Q2 2025 and $195000.0 in Q1 2025.